Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

NCT02630199 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Refractory Cancer

Interventions

DRUG: AZD6738
DRUG: Paclitaxel

Sponsor

Samsung Medical Center